Pyruvate kinase deficiency: cross-border specialty drug access for international patients

Quick orientation

Pyruvate kinase deficiency is rare with an estimated prevalence of 3 to 9 per million people. Higher prevalence is reported in some Amish and Mennonite populations.

Typical age of onset. Severe forms present in infancy; milder forms can present later.

Severity tiers. Severity ranges from compensated hemolysis to transfusion-dependent anemia.

Why specialty drugs for Pyruvate kinase deficiency are hard to access internationally

Pyrukynd (mitapivat) is the first FDA-approved disease-modifying therapy for pyruvate kinase deficiency. International registration is in early stages.

Treatments approved by the FDA

• Pyrukynd (mitapivat) — FDA approval: 2022. Mechanism: Pyruvate kinase activator. Route: Oral twice daily. US WAC ballpark: Approximately USD 380,000 per year. Country pricing: UAE · Egypt · Jordan.

Cross-border pathways used for Pyruvate kinase deficiency

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm PKLR pathogenic variants by genotyping.
• Document hemolysis markers, hemoglobin trend, and transfusion history.
• Liver function and lipid panel monitoring per label.
• Hematologist co-management is essential.

Common questions

How is response measured?

Hemoglobin response, transfusion independence (in transfusion-dependent patients), and hemolysis markers.

Is Pyrukynd approved outside the US?

International registration is rolling out.

Can patients on chronic transfusions benefit?

Some patients achieve transfusion independence on Pyrukynd. Response varies.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Hematologist's prescription, genetic confirmation, transfusion history, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Pyruvate kinase deficiency, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Pyruvate kinase deficiency

Reserved for you.